



ECNG

Extracorporeal Nephrology Group

An Academic Forum for Nephrologists,
DM Trainees, Physicians, and
Healthcare Professionals

FINERENONE IN NON DIABETIC CKD


Beyond Diabetes. Kidney Protection for All.

A selective, non-steroidal mineralocorticoid
receptor antagonist (nsMRA)



Protects the
Kidneys.
Preserves
the Future.

MECHANISM OF ACTION



- ✓ Selectively blocks MR in the kidneys and heart
- ✓ Reduces inflammation and fibrosis
- ✓ Reduces albuminuria and slows CKD progression
- ✓ Cardio-renal protection

WHO CAN BENEFIT?

ADULTS WITH CHRONIC KIDNEY DISEASE (NON DIABETIC)



With albuminuria
(UACR ≥ 30 mg/g)
despite maximum tolerated
ACEi or ARB therapy

eGFR down to **25** ml/min/1.73 m²

POTENTIAL BENEFITS IN NON DIABETIC CKD



SLOWS CKD PROGRESSION

Reduces risk of
sustained eGFR
decline, kidney
failure and need
for dialysis



REDUCES ALBUMINURIA

Significant reduction
in proteinuria
independent of
eGFR effect



CARDIOVASCULAR PROTECTION

Reduces risk of
cardiovascular
events and
hospitalization



WELL TOLERATED

Lower risk of
hyperkalemia
compared to
steroidal MRAs*

*Compared to spironolactone

EVIDENCE BEYOND DIABETES

FIDELIO-DKD (Non-diabetic subgroup)



18% risk reduction in kidney
composite outcome



14% risk reduction in major
cardiovascular events



Benefits consistent across
levels of albuminuria and eGFR

Finerenone benefits are consistent in
diabetic and non-diabetic CKD.

DOSING & MONITORING

STARTING DOSE

eGFR ≥ 60 ml/min/1.73 m²
20 mg once daily

eGFR 25 – 59 ml/min/1.73 m²
10 mg once daily

Titrate to 20 mg once daily
as tolerated

MONITOR



Serum Potassium
Baseline, 4 weeks,
then periodically



eGFR
Baseline and
periodically



Albuminuria
Periodically

PRACTICAL IMPLICATIONS

- ✓ Consider finerenone in adults with non-diabetic CKD with albuminuria despite standard therapy.
- ✓ Monitor serum potassium and kidney function.
- ✓ Add-on therapy for cardiorenal protection.

KEY TAKEAWAYS



Finerenone is effective
in **non diabetic CKD**
with albuminuria.



Reduces risk of CKD
progression and
cardiovascular events.



Use in addition to
ACEi or ARB for
optimal benefit.



Individualize dose
and monitor
regularly.



FINERENONE –
Expanding Renal Protection
Beyond Diabetes



Kidney
Protection



Heart
Protection



Evidence
Based



For Non Diabetic
CKD Patients